Literature DB >> 30285216

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa.   

Abstract

Entities:  

Year:  2018        PMID： 30285216     DOI： 10.1093/annonc/mdy157

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  23 in total

1.  Perspectives on molecular signaling in cancer and update on therapeutic options for the treatment of metastatic cancer.

Authors:  Khalid Sossey-Alaoui
Journal:  Ann Transl Med       Date:  2020-07

2.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

3.  Mitochondrial transcription factor B2 overexpression increases M2 macrophage infiltration via cytosolic mitochondrial DNA-stimulated Interleukin-6 secretion in ovarian cancer.

Authors:  Weilu Wu; Shijie Zhou; Tianmin Liu; Dongni Liang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.

Authors:  Beryl L Manning-Geist; Sushmita B Gordhandas; Dilip D Giri; Alexia Iasonos; Qin Zhou; Jeffrey Girshman; Roisin E O'Cearbhaill; Dmitriy Zamarin; Stuart M Lichtman; Paul J Sabbatini; William P Tew; Karen Li; Autumn S McDonnell; Emeline M Aviki; Dennis S Chi; Carol A Aghajanian; Rachel N Grisham
Journal:  Gynecol Oncol       Date:  2021-11-08       Impact factor: 5.304

5.  EANM guideline on the role of 2-[18F]FDG PET/CT in diagnosis, staging, prognostic value, therapy assessment and restaging of ovarian cancer, endorsed by the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the International Atomic Energy Agency (IAEA).

Authors:  Roberto C Delgado Bolton; Nicolas Aide; Patrick M Colletti; Annamaria Ferrero; Diana Paez; Andrea Skanjeti; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-07-03       Impact factor: 9.236

6.  Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.

Authors:  Pamela M J McLaughlin; Maximilian Klar; Tibor A Zwimpfer; Gilles Dutilh; Marcus Vetter; Christian Marth; Andreas du Bois; Carmen Schade-Brittinger; Alexander Reuss; Claudine Bommer; Christian Kurzeder; Viola Heinzelmann-Schwarz
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

7.  GRHL2 Upregulation Predicts a Poor Prognosis and Promotes the Resistance of Serous Ovarian Cancer to Cisplatin.

Authors:  Yanting Nie; Yiling Ding; Mengyuan Yang
Journal:  Onco Targets Ther       Date:  2020-06-30       Impact factor: 4.147

8.  Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.

Authors:  Laure Thouvenin; Mélinda Charrier; Sophie Clement; Yann Christinat; Jean-Christophe Tille; Mauro Frigeri; Krisztian Homicsko; Olivier Michielin; Alexandre Bodmer; Pierre O Chappuis; Thomas A McKee; Petros Tsantoulis
Journal:  Gynecol Oncol Rep       Date:  2021-05-19

9.  An Italian National Survey on Ovarian Cancer Treatment at first diagnosis. There's None so Deaf as those who will not Hear.

Authors:  Vincenzo Dario Mandato; Federica Torricelli; Stefano Uccella; Debora Pirillo; Gino Ciarlini; Gabriele Ruffo; Gianluca Annunziata; Gloria Manzotti; Sandro Pignata; Lorenzo Aguzzoli
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

Review 10.  Cell competition in intratumoral and tumor microenvironment interactions.

Authors:  Taylor M Parker; Kartik Gupta; António M Palma; Michail Yekelchyk; Paul B Fisher; Steven R Grossman; Kyoung Jae Won; Esha Madan; Eduardo Moreno; Rajan Gogna
Journal:  EMBO J       Date:  2021-08-09       Impact factor: 14.012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.